Weight and Metabolic Outcomes in Naïve HIV Patients Treated with Integrase Inhibitor-Based Antiretroviral Therapy: A Systematic Review and Meta-Analysis
Abstract
:1. Introduction
2. Materials and Methods
2.1. Searches
2.2. Study Selection
2.3. Outcomes
2.4. Data Extraction
2.5. Risk of Bias Assessment
2.6. Statistical Analyses
2.7. Certainty of Evidence
3. Results
3.1. Study Selection
3.2. Study Characteristics
3.3. Risk of Bias Assessment
3.4. Effects of INSTIs on Weight
3.5. Effects of INSTIs on LIPIDS
4. Discussion
4.1. Main Findings
4.2. What Is Known in the Literature about Our Research Question
4.3. What Our Study Adds to the Literature
4.4. Limitations
5. Conclusions
Supplementary Materials
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Conflicts of Interest
References
- Yuh, B.; Tate, J.; Butt, A.A.; Crothers, K.; Freiberg, M.; Leaf, D.; Logeais, M.; Rimland, D.; Rodriguez-Barradas, M.C.; Ruser, C.; et al. Weight change after antiretroviral therapy and mortality. Clin. Infect. Dis. 2015, 60, 1852–1859. [Google Scholar] [CrossRef]
- Bailin, S.S.; Gabriel, C.L.; Wanjalla, C.N.; Koethe, J.R. Obesity and Weight Gain in Persons with HIV. Curr. HIV/AIDS Rep. 2020, 17, 138–150. [Google Scholar] [CrossRef] [PubMed]
- Melchior, J.C.; Salmon, D.; Rigaud, D.; Leport, C.; Bouvet, E.; Detruchis, P.; Vildé, J.L.; Vachon, F.; Coulaud, J.P.; Apfelbaum, M. Resting energy expenditure is increased in stable, malnourished HIV-infected patients. Am. J. Clin. Nutr. 1991, 53, 437–441. [Google Scholar] [CrossRef] [PubMed]
- Shah, S.; Hill, A. Risks of metabolic syndrome and diabetes with integrase inhibitor-based therapy. Curr. Opin. HIV AIDS 2021, 16, 106–114. [Google Scholar] [CrossRef] [PubMed]
- Molina, J.-M.; Capitant, C.; Spire, B.; Pialoux, G.; Cotte, L.; Charreau, I.; Tremblay, C.; Le Gall, J.-M.; Cua, E.; Pasquet, A.; et al. On-demand preexposure prophylaxis in men at high risk for HIV-1 infection. N. Engl. J. Med. 2015, 373, 2237–2246. [Google Scholar] [CrossRef] [PubMed]
- Griesel, R. CYP2B6 genotype and weight-gain differences between dolutegravir and efavirenz. In Proceedings of the Conference on Retroviruses and Opportunistic Infections, Boston, MA, USA, 8–11 March 2020. [Google Scholar]
- Scarsi, K.K.; Havens, J.P.; Podany, A.P.; Avedissian, S.N.; Fletcher, C.V. HIV-1 Integrase Inhibitors: A Comparative Review of Efficacy and Safety. Drugs 2020, 80, 1649–1676. [Google Scholar] [CrossRef]
- Bourgi, K.; Rebeiro, P.F.; Turner, M.; Castilho, J.L.; Hulgan, T.; Raffanti, S.P.; Koethe, J.R.; Sterling, T.R. Greater Weight Gain in Treatment naive Persons starting Dolutegravir-based Antiretroviral Therapy. Clin. Infect. Dis. 2020, 70, 1267–1274. [Google Scholar] [CrossRef]
- Sax, P.E.; Erlandson, K.M.; Lake, J.E.; Mccomsey, G.A.; Orkin, C.; Esser, S.; Brown, T.T.; Rockstroh, J.K.; Wei, X.; Carter, C.C.; et al. Weight gain Following Initiation of Antiretroviral Therapy: Risk Factors in Randomized Comparative Clinical Trials. Clin. Infect. Dis. 2020, 71, 1379–1389. [Google Scholar] [CrossRef]
- Menard, A.; Meddeb, L.; Tissot-Dupont, H.; Ravaux, I.; Dhiver, C.; Mokhtari, S.; Tomei, C.; Brouqui, P.; Colson, P.; Stein, A. Dolutegravir and weight gain: An unexpected bothering side effect? AIDS 2017, 31, 1499–1500. [Google Scholar] [CrossRef]
- Venter, W.D.F.; Moorhouse, M.; Sokhela, S.; Fairlie, L.; Mashabane, N.; Masenya, M.; Serenata, C.; Akpomiemie, G.; Qavi, A.; Chandiwana, N.; et al. Dolutegravir plus Two Different Prodrugs of Tenofovir to Treat HIV. N. Engl. J. Med. 2019, 381, 803–815. [Google Scholar] [CrossRef]
- NAMSAL ANRS 12313 Study Group; Kouanfack, C.; Mpoudi-Etame, M.; Bassega, P.O.; Eymard-Duvernay, S.; Leroy, S.; Boyer, S.; Peeters, M.; Calmy, A.; Delaporte, E. Dolutegravir-based or low-dose efavirenz-based regimen for the treatment of HIV-1. N. Engl. J. Med. 2019, 381, 816–826. [Google Scholar]
- Wohl, D.A.; Yazdanpanah, Y.; Baumgarten, A.; Clarke, A.; Thompson, M.A.; Brinson, C.; Hagins, D.; Ramgopal, M.N.; Antinori, A.; Wei, X.; et al. Bictegravir combined with emtricitabine and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection: Week 96 results from a randomised, double-blind, multicentre, phase 3, non-inferiority trial. Lancet HIV 2019, 6, e355–e363. [Google Scholar] [CrossRef]
- Stellbrink, H.-J.; Arribas, J.R.; Stephens, J.L.; Albrecht, H.; Sax, P.E.; Maggiolo, F.; Creticos, C.; Martorell, C.T.; Wei, X.; Acosta, R.; et al. Co-formulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide for initial treatment of HIV-1 infection: Week 96 results from a randomised, double-blind, multicentre, phase 3, non-inferiority trial. Lancet HIV 2019, 6, e364–e372. [Google Scholar]
- Landovitz, R.J.; Zangeneh, S.Z.; Chau, G.; Grinsztejn, B.; Eron, J.J.; Dawood, H.; Magnus, M.; Liu, A.Y.; Panchia, R.; Hosseinipour, M.C.; et al. Cabotegravir is not associated with weight gain in HIV-uninfected individuals in HPTN 077. Clin. Infect. Dis. 2020, 70, 319–322. [Google Scholar] [CrossRef]
- Nduka, C.U.; Uthman, O.A.; Kimani, P.K.; Stranges, S. Body Fat Changes in People Living with HIV on Antiretroviral Therapy. AIDS Rev. 2016, 18, 198–211. [Google Scholar]
- Eckard, A.R.; Mc Connsey, G.A. Weight gain and Integrase Inhibitors. Curr. Opin. Infect. Dis. 2020, 33, 10–19. [Google Scholar] [CrossRef]
- Page, M.J.; McKenzie, J.E.; Bossuyt, P.M.; Boutron, I.; Hoffmann, T.C.; Mulrow, C.D.; Shamseer, L.; Tetzlaff, J.M.; Akl, E.A.; Brennan, S.E.; et al. The PRISMA 2020 Statement: An updated guideline for reporting systematic reviews. BMJ 2021, 372, n71. [Google Scholar] [CrossRef]
- Sterne, J.A.; Savović, J.; Page, M.J.; Elbers, R.G.; Blencowe, N.S.; Boutron, I.; Cates, C.J.; Cheng, H.Y.; Corbett, M.S.; Eldridge, S.M.; et al. RoB 2: A revised tool for assess- ing risk of bias in randomised trials. BMJ 2019, 366, l4898. [Google Scholar] [CrossRef]
- Veroniki, A.A.; Jackson, D.; Viechtbauer, W.; Bender, R.; Bowden, J.; Knapp, G.; Kuss, O.; Higgins, J.P.; Langan, D.; Salanti, G. Methods to estimate the between-study variance and its uncertainty in meta-analysis. Res. Synth. Methods. 2016, 7, 55–79. [Google Scholar] [CrossRef]
- Knapp, G.; Hartung, J. Improved tests for a random effects meta-regression with a single covariate. Stat. Med. 2003, 22, 2693–2710. [Google Scholar] [CrossRef]
- Higgins, J.P.; Thompson, S.G. Quantifying heterogeneity in a meta-analysis. Stat. Med. 2002, 21, 1539–1558. [Google Scholar] [CrossRef] [PubMed]
- Page, M.J.; Higgins, J.P.T.; Sterne, J.A.C. Chapter 13: Assessing risk of bias due to missing results in a synthesis. In Cochrane Handbook for Systematic Reviews of Interventions, version 6.3 (updated February 2022); Higgins, J.P.T., Thomas, J., Chandler, J., Cumpston, M., Li, T., Page, M.J., Welch, V.A., Eds.; Cochrane: London, UK, 2022; Available online: www.training.cochrane.org/handbook (accessed on 1 March 2022).
- Lennox, J.L.; DeJesus, E.; Lazzarin, A.; Pollard, R.B.; Madruga, J.V.R.; Berger, D.S.; Zhao, J.; Xu, X.; Williams-Diaz, A.; Rodgers, A.J.; et al. Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1. Lancet 2009, 374, 796–806. [Google Scholar] [CrossRef] [PubMed]
- Rockstroh, J.K.; DeJesus, E.; Henry, K.; Molina, J.M.; Gathe, J.; Ramanathan, S.; Wei, X.; Plummer, A.; Abram, M.; Cheng, A.K.; et al. A randomized, double-blind comparison of coformulated elvitegravir/cobicistat/emtricitabine/tenofovir DF vs. ritonavir-boosted atazanavir plus coformulated emtricitabine and tenofovir DF for initial treatment of HIV-1 infection: Analysis of week 96 results. J. Acquir. Immune Syndr. 2013, 62, 483–486. [Google Scholar] [CrossRef] [PubMed]
- Calmy, A.; Sanchez, T.T.; Kouanfack, C.; Mpoudi-Etame, M.; Leroy, S.; Perrineau, S.; Wandji, M.L.; Tata, D.T.; Bassega, P.O.; Bwenda, T.A.; et al. Dolutegravir-based and low-dose efavirenz-based regimen for the initial treatment of HIV-1 infection (NAMSAL): Week 96 results from a two-group, multicenter, randomized, open label, phase 3 non-inferiority trial in Cameroon. Lancet HIV 2020, 7, e677–e687. [Google Scholar] [CrossRef]
- Venter, W.D.; Sokhela, S.; Simmons, B.; Moorhouse, M.; Fairlie, L.; Mashabane, N.; Serenata, C.; Akpomiemie, G.; Masenya, M.; Qavi, A.; et al. Dolutegravir with emtricitabine and tenofovir alafenamide or tenofovir disoproxil fumarate versus efavirenz, emtracitabine, and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection (ADVANCE): Week 96 results from a randomized, phase 3, non-inferiority trial. Lancet HIV 2020, 7, e666–e676. [Google Scholar]
- Walmsley, S.L.; Antela, A.; Clumeck, N.; Duiculescu, D.; Eberhard, A.; Gutiérrez, F.; Hocqueloux, L.; Maggiolo, F.; Sandkovsky, U.; Granier, C.; et al. Dolutegravir plus Abacavir-Lamivudine for the Treatment of HIV-1 infection. N. Engl. J. Med. 2013, 369, 1807–1818. [Google Scholar] [CrossRef]
- Clotet, B.; Feinberg, J.; Van Lunzen, J.; Khuong-Josses, M.A.; Antinori, A.; Dumitru, I.; Pokrovskiy, V.; Fehr, J.; Ortiz, R.; Saag, M.; et al. Once-daily dolutegravir versus darunavir plus ritonavir in antiretroviral-naïve adults with HIV-1 infection (FLAMINGO): 48 week results from the randomized open-label phase 3b study. Lancet 2014, 383, 2222–2231. [Google Scholar] [CrossRef]
- Bai, R.; Lv, S.; Wu, H.; Dai, L. Effects of different integrase strand transfer inhibitors on body weight in patients with HIV/AIDS: A network meta-analysis. BMC Infect. Dis. 2022, 22, 118. [Google Scholar] [CrossRef]
- Kumar, S.; Samaras, K. The Impact of Weight Gain During HIV Treatment on Risk of Pre-diabetes, Diabetes Mellitus, Cardiovascular Disease and Mortality. Front. Endocrinol. 2018, 9, 705. [Google Scholar] [CrossRef]
- Brennan, A.T.; Nattey, C.; Kileel, E.M.; Rosen, S.; Maskew, M.; Stokes, A.C.; Fox, M.P.; Venter, W.D. Change in body weight and risk of hypertension after switching from efavirenz to dolutegravir in adults living with HIV: Evidence from routine care in Johannesburg, South Africa. eClinicalMedicine 2023, 57, 101836. [Google Scholar] [CrossRef]
- Asundi, A.; Olson, A.; Jiang, W.; Varshney, S.P.; White, L.F.; Sagar, M.; Lin, N.H. Integrase inhibitors Use Associated with Weight Gain in Women and Incident Diabetes Mellitus. AIDS Res. Hum. Retrovir. 2022, 38, 208–215. [Google Scholar] [CrossRef]
- Olawepo, J.O.; Pharr, J.R.; Cross, C.L.; Kachen, A.; Olakunde, B.O.; Sy, F.S. Changes in body mass index among people living with HIV who are new on highly active antiretroviral therapy: A systematic review and meta-analysis. AIDS Case 2021, 38, 326–336. [Google Scholar] [CrossRef]
- Pantazis, N.; Papastamopoulos, V.; Antoniadou, A.; Adamis, G.; Paparizos, V.; Metallidis, S.; Sambatakou, H.; Psichogiou, M.; Chini, M.; Chrysos, G.; et al. Changes in Body Mass Index after Initiation of Antirretroviral Treatment Differences by Class of Core Drug. Viruses 2022, 14, 1677. [Google Scholar] [CrossRef]
- Chen, Y.H.; Anderson, D.; Pericone, C.D.; Donga, P. Real-World Assessment of Weight Change in African American Females and Hispanics with HIV-1 After Initiating Strand-Transfer Inhibitors or Protease Inhibitors. JHEOR 2022, 9, 1–10. [Google Scholar] [CrossRef]
- Donga, P.; Emond, B.; Shah, A.; Bookhart, B.K.; Anderson, D.; Vermette-Laforme, M.; Rossi, C.; Lafeuille, M.H. Real-world weight changes in people with HIV-1 at risk of weight gain (female, Black or Hispanic) switching from integrase strand transfer inhibitors. J. Com. Eff. Res. 2023, 12, e220147. [Google Scholar] [CrossRef]
- Raffi, F.; Rachlis, A.; Stellbrink, H.J.; Hardy, W.D.; Torti, C.; Orkin, C.; Bloch, M.; Podzamczer, D.; Pokrovsky, V.; Pulido, F. Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, noninferiority SPRING-2 study. Lancet 2013, 381, 735–743. [Google Scholar] [CrossRef]
- Molina, J.M.; Clotet, B.; van Lunzen, J.; Lazzarin, A.; Cavassini, M.; Henry, K.; Kulagin, V.; Givens, N.; Brennan, C.; de Oliveira, C.F. Once-daily dolutegravir is superior to once daily darunavir/ritonavir in treatment-naïve HIV-1 positive individuals: 96 week from FLAMINGO. J. Int. AIDS Soc. 2014, 17, 19490. [Google Scholar] [CrossRef]
- Quercia, R.; Roberts, J.; Martin-Carpenter, L.; Zala, C. Comparative changes of lipid levels in treatment-naive, HIV-1-infected adults treated with dolutegravir vs. efavirenz, raltegravir, and ritonavir-boosted darunavir-based regimens over 48 weeks. Clin. Drug. Investig. 2015, 35, 211–219. [Google Scholar] [CrossRef]
- Gatell, J.M.; Assoumou, L.; Moyle, G.; Waters, L.; Johnson, M.; Domingo, P. Switching from a ritonavir-boosted protease inhibitor to a dolutegravir-based regimen formaintenance of HIV viral suppression in patients with high cardiovascular risk. AIDS 2017, 31, 2503–2514. [Google Scholar] [CrossRef]
- Llibre, J.M.; Hung, C.C.; Brinson, C.; Castelli, F.; Girard, P.M.; Kahl, L.P.; Blair, E.A.; Angelis, K.; Wynne, B.; Vandermeulen, K.; et al. Efficacy, safety, and tolerability of dolutegravir-rilpivirine for the maintenance of virological suppression in adults with HIV-1: Phase 3, randomised, noninferiority SWORD-1 and SWORD-2 studies. Lancet 2018, 391, 839–849. [Google Scholar] [CrossRef]
- Bagella, P.; Squillace, N.; Ricci, E.; Gulminetti, R.; De Socio, G.V.; Taramasso, L.; Pellicanò, G.; Menzaghi, B.; Celesia, B.M.; Dentone, C.; et al. Lipid profile improvement in virologically suppressed HIV-1 infected patients switched to dolutegravir/abacavir/lamivudine: Data from the SCOLTA project. Infect. Drug. Resist. 2019, 12, 1385–1391. [Google Scholar] [CrossRef] [PubMed]
- The RESPOND Study Group. Incidence of dyslipidemia in people with HIV who are treated with integrase inhibitors versus other antiretroviral agents. AIDS 2021, 35, 869–882. [Google Scholar] [CrossRef] [PubMed]
- Kim, J.; Nam, H.J.; Jung, Y.J.; Lee, H.J.; Kim, S.E.; Kang, S.J. Weight Gain and Lipid Profile Changes in Koreans with Human Immunodeficiency Virus undergoing Integrase Strand Transfer-Inhibitor-Based Regimens. Infect. Chemother. 2022, 54, 419–432. [Google Scholar] [CrossRef]
- Saumoy, M.; Sanchez-Quesada, J.L.; Ordóñez-Llanos, J.; Podzamczer, D. Do All Integrase Strand Transfer Inhbitors Have the Same Lipid Profile? Review of Randomised Controlled Trials in Naïve and Swith Scenarios in HIV–Infected Patients. J. Clin. Med. 2021, 10, 3456. [Google Scholar] [CrossRef] [PubMed]
Author | Year | Country | Drugs | Dose Studied | Male Gender | Age | Follow Up |
---|---|---|---|---|---|---|---|
Lennox [24] | 2009 | Multicentric (Australia, Brazil, Canada, Chile, Colombia, France, Germany, India, Italy, Mexico, Peru, Spain, USA, Thailand) | Raltegravir (n = 281) Efavirenz (n = 282) | 400 mg 600 mg | 81% 82% | 37.6 (9.0) 36.9 (10) | 48 weeks |
Rockstroh [25] | 2013 | Multicentric (USA, Canada, Puerto Rico, Australia, Thailand, Austria, Belgium, Denmark, France, Germany, Italy, Netherlands, Portugal, Sweden, Switzerland, UK, Mexico) | Elvitegravir (n = 353) Atazanavir-ritonavir (n = 355) | 150 mg 300/100 mg | 91.8% 89% | 38 (10.5) 39 (9.8) | 96 weeks |
Calmy [26] | 2020 | Cameroon | Dolutegravir (n = 310) Efavirenz (n = 303) | 50 mg 400 mg | 36.5% 31.7% | 38 (31–46) 36 (29–43) | 96 weeks |
Verter [27] | 2020 | South Africa | Tenofovir alafenamide/emtricitabine + dolutegravir (n = 351) Tenofovir disopropil/emtricitabine/dolutegravir (n = 351) Tenofovir disopropil/emtricitabine/efavirenz (n = 351) | 300/200 + 50 mg 300/200/50 mg 300/200/600 mg | 41% 39% 43% | 32 (8.1%) 33 (7.8%) 32 (7.4%) | 96 weeks |
Walmsley [28] | 2013 | Multicentric (Spain, Belgium, Romania, Germany, France, Italy, USA) | Dolutegravir (n = 414) Efavirenz (n = 419) | 50 mg 600 mg | 84% 85% | 36 (18–63) 35 (18–85) | 48 weeks |
Clotet [29] | 2014 | Multicentric (Spain, USA, Germany, France, Italy, Romania, Russia, Switzerland) | Dolutegravir (n = 242) Darunavir-ritonavir (n = 242) | 50 mg 800/100 mg | 87% 83% | 35.7 (10.6) 36.2 (10.64) | 48 weeks |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Valenzuela-Rodriguez, G.; Diaz-Arocutipa, C.; Collins, J.A.; Hernandez, A.V. Weight and Metabolic Outcomes in Naïve HIV Patients Treated with Integrase Inhibitor-Based Antiretroviral Therapy: A Systematic Review and Meta-Analysis. J. Clin. Med. 2023, 12, 3644. https://doi.org/10.3390/jcm12113644
Valenzuela-Rodriguez G, Diaz-Arocutipa C, Collins JA, Hernandez AV. Weight and Metabolic Outcomes in Naïve HIV Patients Treated with Integrase Inhibitor-Based Antiretroviral Therapy: A Systematic Review and Meta-Analysis. Journal of Clinical Medicine. 2023; 12(11):3644. https://doi.org/10.3390/jcm12113644
Chicago/Turabian StyleValenzuela-Rodriguez, German, Carlos Diaz-Arocutipa, Jaime A. Collins, and Adrian V. Hernandez. 2023. "Weight and Metabolic Outcomes in Naïve HIV Patients Treated with Integrase Inhibitor-Based Antiretroviral Therapy: A Systematic Review and Meta-Analysis" Journal of Clinical Medicine 12, no. 11: 3644. https://doi.org/10.3390/jcm12113644